Irinotecan and Bevacizumab in Glioblastoma-A Review
| Received 10 Mar, 2014 |
Accepted 01 Sep, 2014 |
Published 01 Dec, 2014 |
Glioblastoma is a common brain tumor having comparatively poor prognosis. Bevacizumab and irinotecan are found to be
effective in the treatment of recurrent glioblastoma. The present review covers investigations made on the mentioned drugs in the
past decade. As compared to other chemotherapeutic agents, the drugs have shown greater activity and overall survival when used
as monotherapeutic agents or in combination with other drugs. Still some work needs to be done in establishing clear role of both
the drugs in newly diagnosed glioblastoma, especially, role of irinotecan needs clarity.
How to Cite this paper?
APA-7 Style
Shahid,
M.T., Khair-ul-Bariyah,
S. (2014). Irinotecan and Bevacizumab in Glioblastoma-A Review. Pakistan Journal of Chemistry, 4(1), 1-5. https://doi.org/10.15228/2014.v04.i01.p01
ACS Style
Shahid,
M.T.; Khair-ul-Bariyah,
S. Irinotecan and Bevacizumab in Glioblastoma-A Review. Pak. J. Chem. 2014, 4, 1-5. https://doi.org/10.15228/2014.v04.i01.p01
AMA Style
Shahid
MT, Khair-ul-Bariyah
S. Irinotecan and Bevacizumab in Glioblastoma-A Review. Pakistan Journal of Chemistry. 2014; 4(1): 1-5. https://doi.org/10.15228/2014.v04.i01.p01
Chicago/Turabian Style
Shahid, M., T., and S. Khair-ul-Bariyah.
2014. "Irinotecan and Bevacizumab in Glioblastoma-A Review" Pakistan Journal of Chemistry 4, no. 1: 1-5. https://doi.org/10.15228/2014.v04.i01.p01
This work is licensed under a Creative Commons Attribution 4.0 International License.
